HEALTH PROFESSIONAL · SOURCE READING

Second-line ribociclib and endocrine therapy

Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Metastatic Breast Cancer / Metastatic HER2-Negative Hormone Receptor–Positive Breast Cancer / Endocrine therapy and cyclin-dependent kinase (CDK) inhibitor therapy

The MONALEESA-3 trial included patients receiving second-line therapy. For more information, see the evidence on first-line ribociclib and endocrine therapy above.

Source links and citations

above

Preserved source evidence · Not medical advice